Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1730 views | HTML 2420 views | ?
Ijeoma Adaku Umelo1, Olivier De Wever2, Peter Kronenberger1,3, Jan Van Deun2, Alfiah Noor1, Kshitiz Singh4, Erik Teugels1, Gang Chen1, Marc Bracke2, Jacques De Grève1
1Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis Brussel, Brussels, Belgium
2Laboratory of Experimental Cancer Research and Department of Radiotherapy, Universitair Ziekenhuis Gent, Brussels, Belgium
3Laboratory of Biotechnology, Department of Healthcare, Erasmushogeschool Brussel, Brussels, Belgium
4Laboratory of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium
Jacques De Grève, e-mail: [email protected]
Keywords: lung cancer, KRAS, EGFR, HER, targeted therapy
Received: December 09, 2014 Accepted: May 05, 2015 Published: May 15, 2015
KRAS is a frequently mutated oncogene in lung cancer and among the most refractory to EGFR targeted therapy. Recently, preclinical evidence in pancreatic cancer has demonstrated that mutant KRAS can be regulated by EGFR. However, the distinct correlation between the EGFR/HER family members and mutant KRAS has not been investigated. Here, we show that non-small cell lung cancer cell lines harboring differing isoforms of mutant KRAS, can be broadly divided into EGFR/HER dependent and EGFR/HER independent groups. Combined therapeutic targeting of EGFR, HER2 and HER3 in isoforms regulated by extracellular growth signals promotes in vitro and in vivo efficacy. We also provide evidence that depletion of EGFR via RNA interference specifically abolishes the EGFR/KRAS interaction in the dependent subset. Taken together, these findings suggest that upstream inhibition of the EGFR/HER receptors may be effective in treating a subset of KRAS mutant lung cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.